An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
ConditionUlcerative Colitis (UC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0+
SponsorPfizer
About this trial
A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.
Eligibility criteria
Qualifiers
Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded.
Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Velsipity
Treatment groups
553 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov